SCHEMBL4043373

SCHEMBL4043373

CC(C)CC(C)CNC(=O)C(C1CCCCC1)C1(c2ccc(Cl)cc2)Nc2cc(F)c(F)cc2N1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSD P07339 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
CCR3 P51677 2/20 0.35
NR1H4 Q96RI1 4/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C9 P11712 2/20 0.34
KCNH2 Q12809 2/20 0.34
METAP2 P50579 2/20 0.34
EPHX1 P07099 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
SLC6A9 P48067 1/20 0.33
REN P00797 1/20 0.33
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
MC4R P32245 1/20 0.32
CCR1 P32246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4034789 0.95 ALPL (0.36) CTSDSMN1; SMN2CCR3NR1H4CYP3A4
SCHEMBL4037882 0.91 CTSD (0.36) CTSDSMN1; SMN2CCR3NR1H4METAP2
SCHEMBL1838873 0.81 SLC6A3 (0.42) NR1H4CYP3A4CYP2D6CYP2C9KCNH2
SCHEMBL4035029 0.81 NR1H4 (0.47) SMN1; SMN2NR1H4CYP3A4CYP2D6CYP2C9
SCHEMBL4040844 0.81 NR1H4 (0.47) SMN1; SMN2NR1H4CYP3A4CYP2D6CYP2C9
SCHEMBL1840331 0.80 EPHX1 (0.42) CTSDEPHX1
SCHEMBL1838714 0.80 TP53 (0.38) SMN1; SMN2NR1H4CYP3A4CYP2D6CYP2C9
SCHEMBL1842727 0.79 TSHR (0.39) NR1H4CYP3A4CYP2D6CYP2C9KCNH2
SCHEMBL1843552 0.79 TSHR (0.39) NR1H4CYP3A4CYP2D6CYP2C9KCNH2
SCHEMBL1838067 0.79 MAPT (0.40) SMN1; SMN2NR1H4CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed